Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design

Journal of Medicinal Chemistry

Volumn 39, Issue 24, 1996, Pages 4775-4782

  Prokai Tatrai, Katalin ^a   Prokai, Laszlo ^a   Bodor, Nicholas ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE ENKEPHALIN DERIVATIVE;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; DRUG DESIGN; DRUG EFFECT; DRUG PENETRATION; DRUG RECEPTOR BINDING; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT;

ANALGESIA; ANALGESICS; BLOOD-BRAIN BARRIER; BRAIN; DIPEPTIDYL PEPTIDASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENKEPHALIN, LEUCINE; ESTERASES; LIPASE; NALOXONE; NICOTINE; PEPTIDES; PRODRUGS; RECEPTORS, OPIOID;

EID: 0030471676     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960356e     Document Type: Article

References (45)

1. Hughes, J. A. H.; Smith, T. W. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (London) 1975, 258, 577-579.
2. (a) Olson, G. A.; Olson, R. D.; Kastin, A. J. Endogeneous opiates: 1984. Peptides 1985, 6, 769-771.
3. (b) Baile, C. A.; McLaughlin, C. L.; Della-Fera, M. A. Role of cholecytokinin and opioid peptides in control of food intake. Physiol. Rev. 1986, 66, 172.
4. Malik, J. B.; Goldstein, J. M. Analgesic activity of enkephalins following intracerebral administration in the rats. Life Sci. 1977, 20, 827-832.
5. Chaillet, P.; Coulaud, A.; Zajac, J.-M.; Fournie-Zaluski, M.-C.; Costentin, J.; Roques, B. The μ rather than the δ subtype of opioid receptors appears to be involved in the enkephalin-induced analgesia. Eur. J. Pharmacol. 1984, 101, 83-90.
6. Hambrook, J. M.; Morgan, B. A.; Rance, M. J.; Smith, C. F. Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenate. Nature (London) 1976, 262, 782-783.
7. Malfroy, B.; Swerts, J. P.; Guyon, A.; Roques, B. P.; Schwartz, J. C. High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature (London) 1978, 276, 523-526.
8. Nakajima, S.; Komuro, T.; Shimamura, M.; Hazato, T. Enkephalin-binding protein in human blood. Biochem. Int. 1989, 19, 529-536.
9. (a) Paterson, S. J.; Corbett, A. D.; Gillan, M. G. C.; Koaterlitz, H. W.; Knight, A. T.; Robson, L. E. Radioligands for probing opioid receptors. J. Recept. Res. 1984, 4, 143-145.
10. 61-64 possessing μ selective agonist activity at opiate receptors. Eur. J. Pharmacol. 1981, 70, 531-540.
11. 2-Met-Enkephalinamide: A potent, long-lasting synthetic pentapeptide analgesic. Science 1976, 194, 330-332.
12. (b) Tortella, F. C.; Robles, L.; Holaday, J. W. The anticonvulsant effects of DADLE are primarly mediated by activation of δ opioid receptors: interaction between δ and μ receptor agonists. Life Sci. 1985, 37, 497-503.
13. Prokai, L. Delivery of peptides into the central nervous system. Drug Discovery Today 1996, 1, 161-167.
14. (a) Brownlees, J.; Williams, C. H. Peptidases, peptides, and the mammalian blood-barrier. J. Neurochem. 1993, 60, 793-803.
15. (b) Begley, D. J.; Squires, L. K.; Zlokovic, B. W.; Mirtovic, D. M.; Hughes, C. C. W.; Revest, P. A.; Greenwood, J. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J. Neurochem. 1990, 55, 1222-1230.
16. Bodor, N.; Prokai, L.; Wu, W.-M.; Farag, H.; Jonalagadda, S.; Kawamura, M.; Simpkins, J. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992, 257, 1698-1700.
17. Bodor, N.; Prokai, L. Molecular packaging. Peptide delivery to the central nervous system by sequential metabolism. In Peptide-Based Drug Design; Taylor, M. D., Amidon, G, L., Eds.; American Chemical Society: Washington, DC, 1995; pp 317-337.
18. Prokai, L.; Ouyang, X.-D.; Wu, W.-M.; Bodor, N. Chemical delivery system to transport amide to the central nervous system. J. Am. Chem. Soc. 1994, 116, 2643-2644.
19. Bodor, N. Retrometabolic approaches to drug targeting. NIDA Res. Monogr. Series 1995, 154, 1-26.
20. Bodor, N. Drug Targeting and Retrometabolic Drug Design Approaches. Adv. Drug Delivery Rev. 1994, 14, 157-166.
21. 5-enkephalin. Eur. J. Pharm. 1978, 47, 223-225.
22. (a) Hoek, J.; Rydstrom, J. Physiological roles of nicotinamide nucleotide transhydrogenase. J. Biochem. 1988, 254, 1-10.
23. (b) Bodor, N.; Kaminsky, J. Reactivity of biologically important reduced pyridines I. Correlation between hydride transfer and one-electron oxidation of dihydropyridines and heterocycles. J. Mol. Struct. (THEOCHEM) 1988, 163, 315-330.
24. (c) Brewster, M.; Kaminski, J.; Bodor, N. Reactivity of biologically important reduced pyridines. 2. The oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). An MNDO study. J. Am. Chem. Soc. 1988, 110, 6377-6341.
25. (d) Bodor, N.; Brewster, M.; Kaminski, J. Theoretical studies on the hydride transfer between 1-methyl-1,4-dihydronicotinamide and its corresponding pyridinium salt. Tetrahedron 1988, 44, 7601-7610.
26. (e) Bodor, N.; Brewster, M.; Kaminski, J. Reactivity of biologically important reduced pyridines III. Energetics and mechanism of hydride transfer between 1-methyl-1,4-dihydronicotinamide and 1-methylnicotinamide cation. J. Mol. Struct. (THEOCHEM) 1990, 206, 315-334.
27. (a) Bodor, N.; Nakamura, T.; Brewster, M. E. Improved delivery through biological membranes XXIII: Synthesis, distribution and neurochemical effects of a tryptamine chemical delivery systems. Drug Des. Delivery 1986, 1, 56-64.
28. (b) Pop, E.; Brewster, M. E.; Bodor, N. Site-specific delivery of the central nervous system acting amines. Drugs Future 1991, 16, 919-944.
29. Schwartz, J.; Giros, B.; Gros, C.; Llorens-Cortes, C.; Arrang, J.; Garbag, M.; Pollard, H. Novel agents affecting enkephalinergic and histaminergic transmissions in the brain. Cephalagia 1987, 7, 32-35.
30. Yoshimoto, T.; Fischl, M.; Orlowski, R. C.; Walter, R. J. Post-proline cleaving enzyme and post-proline dipeptidyl aminopeptidase. Comparison of two peptidases with high specificity for proline residues. J. Biol. Chem. 1978, 253, 3708-3716.
31. py-alkylated 3-D-pyridylalanines. In Peptides: Chemistry, Structure and Biology; Proceedings of the Thirteenth American Peptide Symposium; Hodges, R. S., Smith, J. A., Eds.; ESCOM: Leiden, 1994, pp 565-567.
32. 2]Leu-enkephalin derivatives conjugated with the 1-adamantane moiety. Biochem. Pharmacol. 1991, 41, R5-R8.
33. Coste, J.; Le Nguyen, D.; Castro, B. PyBOP: a new peptide coupling reagent devoid of toxic by-product. Tetrahedron Lett. 1990, 18, 1469-1472.
34. Kisfaludy, L.; Low, M.; Nyeki, O.; Szirtes, T.; Schon, I. Die Verwendung von Pentafluorophenylestern bei Peptidsynthesen. (The use of pentafluorophenyl esters for peptide synthesis.) Ann. Chem. 1973, 1421-1429.
35. Eisner, V.; Kuthan, J. The chemistry of dihydropyridines. Chem. Rev. 1972, 72, 1-42.
36. 50 measured for the intermediates 16 may be, in part, due to the slow release of DADLE.
37. Valentino, R. J.; Katz, J. L.; Medzihradsky, F.; Woods, J. H. Receptor binding, antagonist, and withdrawal. Neuroscience 1983, 32, 2887-2896.
38. Bodanszky, M. Active Esters in Peptide Synthesis. In Peptides; Gross, E., Meienhofer, J., Eds.; Academic Press, New York; 1979; Vol. 1, pp 105-196.
39. Bodor, N.; Buchwald, P. Estimating the role of the van der Waals molecular size in solute partitioning. J. Pharm. Sci., submitted for publication.
40. Prokai, L.; Hsu, B. H.; Bodor, N. Desorption chemical ionization, thermospray, and fast atom bombardment mass spectrometry of dihydropyridine ⇌ pyridinium salt-type redox systems. Anal. Chem. 1989, 61, 1723-1728.
41. Kaiser, E.; Colescott, R. I.; Bossinger, C. D.; Cook, P. I. Color test for detection of free amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
42. Hochhaus, G.; Yu, V. C.; Sadee, W. Delta opioid receptors in human neuroplasma cell lines. Brain Res. 1986, 382, 327-333.
43. Brewster, M. E. Parental safety and application of 2-hydroxypropyl-β-cyclodextrin. In New Trends in Cyclodextrins; Duchene, D., Ed.; Editions de Sante Publishers: Paris, 1991; pp 315-350.
44. (a) Greig, N.; Sweeney, D.; Rapoport, S. Inability of dimethyl sulfoxide to increase brain uptake of water-soluble compounds: Implications to chemotherapy for brain tumors. Cancer Treat. Rep. 1985, 69, 305-312.
45. (b) Neuwelt, E. A.; Barnett, P.; Barranger, J.; McCormick, C.; Pagel, M.; Frenkel, E. Inability of dimethyl sulfoxide and 5-fluorouracil to open the blood-brain barrier. Neurosurgery 1983, 12, 29-34.